Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 11, 2009, Pages 1716-1723

  Yilmaz, Mahmut Ilker ^a   Carrero, Juan Jesús ^b   Ortiz, Alberto ^c   Martín Ventura, Jose Luis ^c   Sonmez, Alper ^a   Saglam, Mutlu ^a   Yaman, Halil ^a   Yenicesu, Mujdat ^a   Egido, Jesús ^c   Blanco Colio, Luis Miguel ^c  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLYCOPROTEIN; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; VASODILATATION;

ADULT; APOPTOSIS; BIOLOGICAL MARKERS; ENDOTHELIAL CELLS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; REGRESSION ANALYSIS; RENAL CIRCULATION; RENAL INSUFFICIENCY, CHRONIC; TUMOR NECROSIS FACTORS;

EID: 73449115326     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02760409     Document Type: Article

References (43)

1. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 105: 1135-1143, 2002
2. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA: The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42: 1149-1160, 2003
3. Vita JA, Keaney JF Jr: Endothelial function: A barometer for cardiovascular risk? Circulation 106: 640-642, 2002
4. Endemann DH, Schiffrin EL: Endothelial dysfunction. J Am Soc Nephrol 15: 1983-1992, 2004
5. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101: 948-954, 2000
6. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32: S112-S119, 1998
7. Tonelli M, Pfeffer MA: Kidney disease and cardiovascular risk. Annu Rev Med 58: 123-139, 2007
8. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia I, Browning JL: TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 272: 32401-32410, 1997
9. Winkles JA: The TWEAK-Fn14 cytokine-receptor axis: Discovery, biology and therapeutic targeting. Nat Rev Drug Discov 7: 411-425, 2008
10. Wiley SR, Winkles JA: TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 14: 241-249, 2003
11. Marsters SA, Sheridan JP, Pitti RM, Brush J, Goddard A, Ashekenazi A: Identification of a ligand for the deathdomain containing receptor Apo3. Curr Biol 8: 525-528, 1998
12. Desplat-Jego S, Varriale S, Creidy R, Terra R, Bernard D, Khrestchatisky M, Izui S, Chicheportiche Y, Boucraut J: TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity. J Neuroimmunol 133: 116-123, 2002
13. Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR: TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 274: 8455-8459, 1999
14. Polek TC, Talpaz M, Darnay BG, Spivak-Kroizman T: TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR: Evidence for a second TWEAK receptor. J Biol Chem 278: 32317-32323, 2003
15. Ho DH, Vu H, Brown SA, Donohue PJ, Hanscom HN, Winkles JA: Soluble tumor necrosis factor-like weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. Cancer Res 64: 8968-8972, 2004
16. Kim SH, Kang YJ, Kim WJ, Woo DK, Lee Y, Kim DI, Park YB, Kwon BS, Park JE, Lee WH: TWEAK can induce proinflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J 68: 396-399, 2004
17. Saas P, Boucraut J, Walker PR, Quiquerez AL, Billot M, Desplat-Jego S, Chicheportiche Y, Dietrich PY: TWEAK stimulation of astrocytes and the proinflammatory consequences. Glia 32: 102-107, 2000
18. Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S: TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem 278: 36005-36012, 2003
19. Carrero JJ, Ortiz A, Qureshi AR, Martín-Ventura JL, Bárány P, Heimbürger O, Marrón B, Metry G, Snaedal S, Lindholm B, Egido J, Stenvinkel P, Blanco-Colio LM: Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 4: 110-118, 2009
20. Blanco-Colio LM, Martin-Ventura JL, Munoz-Garcia B, Orbe J, Paramo JA, Michel JB, Ortiz A, Meilhac O, Egido J: Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 27: 916-922, 2007
21. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42[Suppl 3]:S1-S202, 2004
22. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470, 1999
23. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 18: 499-502, 1972
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985
25. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340: 1111-1115, 1992
26. Kralisch S, Ziegelmeier M, Bachmann A, Seeger J, Lossner U, Bluher M, Stumvoll M, Fasshauer M: Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis 199: 440-444, 2008
27. Harada N, Nakayama M, Nakano H, Fukuchi Y, Yagita H, Okumura K: Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun 299: 488-493, 2002
28. Donohue PJ, Richards CM, Brown SA, Hanscom HN, Buschman J, Thangada S, Hla T, Williams MS, Winkles JA: TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 23: 594-600, 2003
29. Blanco-Colio LM, Martín-Ventura JL, Sol JM, Díaz C, Hernández G, Egido J: Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: Normalization by atorvastatin. J Am Coll Cardiol 43: 1188-1194, 2004
30. Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Martineau P, Hérnandez G, Egido J: ACTFAST investigators: Increased soluble Fas plasma levels in subjects at high cardiovascular risk - Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST. Arterioscler Thromb Vasc Biol 27: 168-174, 2007
31. Blanco-Colio LM, Martín-Ventura JL, Tuñón J, García-Camarero T, Berrazueta JR, Egido J: Soluble Fas ligand plasma levels are associated with forearm reactive hyperemia in subjects with coronary artery disease: A novel biomarker of endothelial function? Atherosclerosis 201: 407-412, 2008
32. Zhao Z, Burkly LC, Campbell S, Schwartz N, Molano A, Choudhury A, Eisenberg RA, Michaelson JS, Putterman C: TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol 179: 7949-7958, 2007
33. Sanz AB, Justo P, Sanchez-Nino MD, Blanco-Colio LM, Winkles JA, Kreztler M, Jakubowski A, Blanco J, Egido J, Ruiz-Ortega M, Ortiz A: The cytokine TWEAK modulates renal tubulointerstitial inflammation. J Am Soc Nephrol 19: 695-703, 2008
34. Munoz-Garcia B, Martin-Ventura JL, Martinez E, Sanchez S, Hernandez G, Ortega L, Ortiz A, Egido J, Blanco-Colio LM: Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: Modulation by atorvastatin. Stroke 37: 2044-2053, 2006
35. Moreno JA, Muñoz-García B, Martín-Ventura JL, Madrigal-Matute J, Orbe J, Páramo JA, Ortega L, Egido J, Blanco-Colio LM: The CD163-expressing macrophages recognize and internalize TWEAK potential consequences in atherosclerosis. Atherosclerosis May 3, 2009 [epub ahead of print]
36. Axelsson J, Møller HJ, Witasp A, Qureshi AR, Carrero JJ, Heimbürger O, Bárány P, Alvestrand A, Lindholm B, Moestrup SK, Stenvinkel P: Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD. Am J Kidney Dis 48: 916-925, 2006
37. Bover LC, Cardo-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, Aggarwal BB, Arap W, Pasqualini R: A previously unrecognized protein-protein interaction between TWEAK and CD163: Potential biological implications. J Immunol 178: 8183-8194, 2007
38. Wenzel K, Ernst M, Rohde K, Baumann G, Speer A: DNA polymorphisms in adhesion molecule genes: A new risk factor for early atherosclerosis. Hum Genet 97: 15-20, 1996
39. Testa A, Benedetto F, Spoto B, Pisano A, Tripepi G, Mallamaci F, Malatino LS, Zoccali C: The E-selectin gene polymorphisms and carotid atherosclerosis in end-stage renal disease. Nephrol Dial Transplant 21: 1921-1926, 2006
40. Malatino LS, Stancanelli B, Cataliotti A, Bellanuova I, Fatuzzo P, Rapisarda F, Leonardis D, Tripepi G, Mallamaci F, Zoccali C: Circulating E-selectin as a risk marker in patients with end-stage renal disease. J Intern Med 262: 479-487, 2007
41. Ortiz A, Sanz AB, García BM, Moreno JA, Niño MD, Martín-Ventura JL, Egido J, Blanco-Colio LM: Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine Growth Factor Rev 20: 251-258, 2009
42. Jain M, Jakubowski A, Cui L, Shi J, Su L, Bauer M, Guan J, Lim CC, Naito Y, Thompson JS, Sam F, Ambrose C, Parr M, Crowell T, Lincecum JM, Wang MZ, Hsu YM, Zheng TS, Michaelson JS, Liao R, Burkly LC: A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure. Circulation 119: 2058-2068, 2009
43. Blanco-Colio LM, Martín-Ventura JL, Muñoz-Garcia B, Moreno JA, Meilhac O, Ortiz A, Egido J: TWEAK and Fn14: New players in the pathogenesis of atherosclerosis. Front Biosci 12: 3648-3655, 2007